Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin Pharmaceutical Da Ren Tang Group Buyback Yield % Chart
Tianjin Pharmaceutical Da Ren Tang Group Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin Pharmaceutical Da Ren Tang Group Buyback Yield % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) has a Buyback Yield % of 0.00 as of Jul. 28, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. According to the industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #999999 out of 290 companies in the Drug Manufacturers industry.
Is Tianjin Pharmaceutical Da Ren Tang Group's Buyback Yield % too high?
Tianjin Pharmaceutical Da Ren Tang Group's current Buyback Yield % is 0.00. Based on the distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #999999 out of 290 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's Buyback Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianjin Pharmaceutical Da Ren Tang Group ranks #999999 out of 290 companies for Buyback Yield %. This places Tianjin Pharmaceutical Da Ren Tang Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. Tianjin Pharmaceutical Da Ren Tang Group's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥23.63, compared to a current price of ¥36.43 — trading 54.2% above its estimated fair value. The current Buyback Yield % is 0.00. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329), the current Buyback Yield % is 0.00 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued.
The current stock price of ¥36.43 is trading 54.2% above its estimated GF Value™ of ¥23.63.
GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.
Key valuation signals for SHSE:600329:
Buyback Yield %: 0.00
GF Value™: ¥23.63 vs. price of ¥36.43 (54.2% above fair value)
No single metric tells the full story. See the SHSE:600329 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin Pharmaceutical Da Ren Tang Group Business Description
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
65GF Score
Get the complete analysis for SHSE:600329
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600329 has been successfully added to your 
